Ibrahim Zabaneh, MD
Family Medicine · Hobart, INNPI 1578555496
Payments from drug & device makers
Across 469 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$825
- GSK$799
- Novo Nordisk$639
- Intuitive Surgical$586
- Novartis$471
- Sanofi-aventis U.S. LLC$455
- plus $5K from 31 others
What the payments were for
- Travel & lodging$5867%
- Food & beverage$7,71492%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $825 |
| GSK | 43 | $799 |
| Novo Nordisk | 59 | $639 |
| Intuitive Surgical | 2 | $586 |
| Novartis | 11 | $471 |
| Sanofi-aventis U.S. LLC | 31 | $455 |
| Astellas Pharma US Inc | 21 | $446 |
| Lilly USA, LLC | 22 | $410 |
| AstraZeneca | 17 | $390 |
| Amgen | 33 | $389 |
| Sunovion Pharmaceuticals Inc. | 22 | $377 |
| Pfizer | 29 | $351 |
| Merck | 31 | $298 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $187 |
| Johnson & Johnson | 11 | $172 |
| Apollo Endosurgery US Inc | 1 | $171 |
| Stryker | 1 | $171 |
| Genentech USA, Inc. | 1 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $137 |
| Boston Scientific | 1 | $127 |
| Amarin Pharma, Inc. | 8 | $117 |
| Bayer | 1 | $115 |
| Dexcom, Inc. | 6 | $95 |
| Arbor Pharmaceuticals, Inc. | 6 | $81 |
| Boehringer Ingelheim | 5 | $77 |
| Phathom Pharmaceuticals, Inc. | 5 | $75 |
| Eisai Inc. | 4 | $60 |
| Valeritas, Inc. | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| IBSA Pharma Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Corium, LLC | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$549
- X-Tack Endoscopic HeliX Tacking System$343
- ENTRESTO$245
- OverStitch Endoscopic Suturing System$171
- ORBERA Intragastric Balloon System$171
- ACTISHIELD CF$171
- XOLAIR$150
- TRULICITY$138
- Watchman$127
- TRULANCE$125
- FASENRA$125
- TRELEGY ELLIPTA$117
- Kerendia$115
- ELIQUIS$104
- Ozempic$102
How this compares
$8,394 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $141,250 |
| JardianceEmpagliflozin | 83 | $91,614 |
| TrulicityDulaglutide | 54 | $91,545 |
| MounjaroTirzepatide | 67 | $82,791 |
| JanuviaSitagliptin Phosphate | 57 | $67,709 |
| LinzessLinaclotide | 46 | $45,143 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 33 | $43,218 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $42,714 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $33,139 |
| RybelsusSemaglutide | 16 | $31,727 |
| Praluent PenAlirocumab | 30 | $26,312 |
| FarxigaDapagliflozin Propanediol | 24 | $22,908 |
| EntrestoSacubitril/Valsartan | 24 | $20,033 |
| TradjentaLinagliptin | 12 | $17,710 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $17,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $639 | $216,194145 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25 | $410 | $177,187134 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $77 | $121,141112 claims |
| MerckJanuvia, Janumet Xr | $298 | $75,83270 claims |
| AbbVieLinzess, Synthroid | $825 | $50,688136 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $455 | $42,71436 claims |
| AstraZenecaFarxiga, Symbicort | $390 | $31,65949 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $799 | $24,91041 claims |
| NovartisEntresto | $471 | $20,03324 claims |
| Johnson & JohnsonXarelto | $172 | $14,35915 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $81 | $13,68626 claims |
| PfizerEliquis | $351 | $12,99518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Hobart
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.